FDA warned Free State Oils over website claims that its CBD products treat disease, including COVID-19, and are unapproved drugs and adulterated foods.
What happened
FDA reviewed www.freestateoils.com in May 2022 and the company's Facebook, Instagram, and Twitter accounts, which direct consumers to the website. FDA found the company offered CBD products for humans and animals with claims to mitigate, prevent, treat, diagnose, or cure diseases, including COVID-19 in people. FDA determined the animal CBD products were unapproved new animal drugs, the human CBD products were unapproved and misbranded new drugs, and certain CBD foods contained an unsafe food additive.
What FDA found
The CBD products for animals are unapproved new animal drugs and are unsafe because FDA has not approved or index-listed them.
FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)The CBD products for humans are unapproved new drugs sold without FDA approval.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The human CBD products are misbranded because their labeling lacks adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)CBD Honey Straws and CBD Gum Drops are adulterated foods because CBD is an unsafe food additive for their use.
FD&C Act section 402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)Whisper’s Soothing Grains CBD for Farm Animals and Snoop’s Chews CBD Dog Treats are animal foods with added CBD, which FDA considers a prohibited act under section 301(ll).
FD&C Act section 301(ll), 21 U.S.C. 331(ll)The company’s CBD products are not lawful dietary supplements because CBD is excluded from the dietary supplement definition.
FD&C Act sections 201(ff)(3)(B)(i) and (ii), 21 U.S.C. 321(ff)(3)(B)(i) and (ii)
What FDA wants
FDA requests immediate action to cease sale of any unapproved and unauthorized products for COVID-19 and any unapproved CBD products for food-producing animals. It also says the products must not be introduced or delivered for introduction into interstate commerce.
Who should pay attention
- CBD brands and retailers making disease-treatment claims
- makers of CBD pet treats and farm-animal feeds
- companies selling CBD foods or supplements that depend on GRAS or dietary-supplement status
This is a summary. Read the original letter on fda.gov.